Vistagen Therapeutics Reports Increased Net Losses and Revenue Growth for December 2025 Quarter

Vistagen Therapeutics, Inc. reported its financial results for the three and nine months ended December 31, 2025, revealing a net loss of $18.9 million for the quarter and $53.4 million for the nine-month period. This represents an increase in losses compared to the same periods in the previous fiscal year, where the net loss was $14.1 million and $37.8 million, respectively. The company's total revenues for the quarter were $303,000, up from $234,000 in the prior year, while revenues for the nine months increased to $804,000 from $501,000, primarily due to revenue recognized under the AffaMed Agreement.

Operating expenses for the three months ended December 31, 2025, totaled $19.8 million, compared to $15.4 million in the same quarter of 2024. The increase was driven by higher research and development costs, which rose to $14.2 million from $11.3 million, largely due to expenses associated with the ongoing PALISADE program for fasedienol, aimed at treating social anxiety disorder (SAD). General and administrative expenses also increased to $5.6 million from $4.0 million, reflecting higher consulting and professional fees.

In terms of strategic developments, Vistagen has been actively advancing its clinical pipeline, which includes five clinical-stage pherine product candidates. The company is focusing on fasedienol, which is currently in multiple Phase 3 trials for SAD. The PALISADE-2 trial achieved its primary endpoint, while PALISADE-1 and PALISADE-3 did not. The company is also preparing for the PALISADE-4 trial and a Repeat Dose Study, with topline data expected in the first half of 2026. Additionally, Vistagen entered into an Exclusive Negotiation Agreement with Fuji Pharma for the potential development of refisolone in Japan, receiving a $1.5 million payment as part of this agreement.

As of December 31, 2025, Vistagen reported cash, cash equivalents, and marketable securities totaling approximately $61.8 million, a decrease from $80.5 million at the end of the previous fiscal year. The company experienced a net cash outflow of $50.2 million from operating activities during the nine months, compared to $32.0 million in the same period last year. The company has indicated that it may need to seek additional capital to fund its operations and continue its development programs, as it has not yet generated significant revenue from its product candidates.

Looking ahead, Vistagen faces challenges related to its financial position, including a letter from Nasdaq indicating non-compliance with the minimum bid price requirement for continued listing. The company has until August 3, 2026, to regain compliance. Management has expressed uncertainty about its ability to fund operations beyond twelve months from the issuance date of the financial statements, highlighting the need for additional financing and the potential impact on its ongoing research and development activities.